The purpose of the SPORE Developmental Research Program is to encourage and develop research projects that will lead to clinically testable hypotheses that will reduce ovarian cancer incidence and mortality or improve survival and quality of life. Three or more projects will be funded annually, for 1 year, and will be renewable for 1 additional year. The objectives of the Developmental Research Program are to: ? Publicize the availability of start-up funding for pilot projects in ovarian cancer translational research. ? Identify projects that are innovative and have significant potential for reducing ovarian cancer incidence and mortality or for improving survival and quality of life. ? Encourage collaborations among scientists within and outside the SPORE environment. ? Help potential pilot project investigators to define and articulate translational research goals and the steps required to meet them. ? Select competing research proposals for funding using internal and external reviewers applying specific criteria. ? Provide developmental funding for investigators in the SPORE institution and scientists at other selected sites. ? Develop a mechanism for the SPORE PI and Co-Pi to closely monitor and work with the Developmental Project investigators to assist them in achieving their translational research goals. ? Administer a flexible program in which pilot projects that demonstrate promise follow one of three courses: funding for another year, elevation to full SPORE projects, or encouragement to apply for research support outside of the SPORE mechanism. Developmental projects that do not reach their potential will be terminated. One recipient of developmental funding has become Co-Pi of a full SPORE project. Overall, the SPORE has funded 17 of 61 proposals submitted, and these have resulted in 20 published papers (plus seven now under review and seven in preparation) and 11 funded grants, seven of which deal directly with ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083639-10
Application #
7933950
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
10
Fiscal Year
2009
Total Cost
$177,918
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Seo, Hyeonglim; Choi, Ikjang; Whiting, Nicholas et al. (2018) Hyperpolarized Porous Silicon Nanoparticles: Potential Theragnostic Material for 29 Si Magnetic Resonance Imaging. Chemphyschem 19:2143-2147
Mitamura, T; Pradeep, S; McGuire, M et al. (2018) Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37:722-731
Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9
Liu, Xiaojun; Jiang, Yingjun; Nowak, Billie et al. (2018) Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 81:255-267
Haemmerle, Monika; Stone, Rebecca L; Menter, David G et al. (2018) The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33:965-983
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473
Yang, Hailing; Mao, Weiqun; Rodriguez-Aguayo, Cristian et al. (2018) Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24:5072-5084

Showing the most recent 10 out of 648 publications